Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Sorrento Therapeutics Inc (OQ:SRNE)

Business Focus: Bio Therapeutic Drugs

INK Edge Outlook

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEC Form 4 filings for SRNE*US within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Sep 19, 2021 14:58 ET
Sorrento Announces an Independent Real-World Study That Reports Superior Sensitivity Results in Detecting COVID-19 Virus Infections in All-Comer General Population by COVISTIX as Compared to a Globall
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19, today announced impressive...
Read full article
Sep 13, 2021 09:00 ET
Dr. Henry Ji, Sorrento Chairman and CEO, to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the H.C. Wainwright 23rd Global Investment Conference (www.hcwevents.com/annualconference). The conference is being...
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
2.39
--
--
Price to Sales - TTM
46.74
12.80
8.12
Price to Book - most recent quarter
12.48
3.69
3.46
Price to Cash Flow per share - TTM
--
13.53
16.30
Price to Free Cash Flow per share - TTM
--
20.35
29.76
See all valuations

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Sorrento Therapeutics, Inc. is a clinical-stage, antibody-centric, biopharmaceutical company developing therapies to treat cancers and COVID-19. The Company's segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around Immune-Oncology therapeutic area, leveraging its proprietary G-MAB antibody library and targeted delivery modalities to generate the next generation of cancer therapeutics. The Scilex segment is largely organized around its non-opioid pain management operations. The Company's multimodal, multipronged approach to fighting cancer is made possible by immuno-oncology platforms, including key assets such as fully human antibodies, clinical-stage immuno-cellular therapies, antibody-drug conjugates, and clinical-stage oncolytic virus. It is also developing potential antiviral therapies and vaccines against coronaviruses, which includes COVI-GUARD, COVI-AMG, COVI-SHIELD, Gene-MAb, COVI-MSC, and COVI-DROPS.

See business summary

 

Twitter

Search (past week) for $SRNE